Cancer immunotherapeutic targeting tropomyosin receptor kinase C (TrkC) through its conjugate and cyclophosphamide
IYIY-DNP+CTX significantly reduced TrkC<sup>+</sup> tumor growth by suppressing immunosuppressive factors and enhancing immune-stimulating responses, helping the immune system fight cancer more effectively.
Authors
- Lik Voon Kiew (ORCID: https://orcid.org/0000-0002-6855-9631)
- Chin Siang Kue (ORCID: https://orcid.org/0000-0002-9793-5616)
- Siti Nursyahirah Bakar (ORCID: https://orcid.org/0000-0003-2821-6770)
- Lip Yong Chung (ORCID: https://orcid.org/0000-0002-3596-768X)
- Kevin Burgess (ORCID: https://orcid.org/0000-0001-6597-1842)
Institutions
- University Malaya Medical Centre (MY)
- Management and Science University (MY)
- National Yang Ming Chiao Tung University (TW)
- University of Malaya (MY)
- Innovative Clinical Research (US)
- Health & Life (Taiwan) (TW)
- Texas A&M University (US)
Publication Details
- Journal
- Immunopharmacology and Immunotoxicology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1080/08923973.2025.2572078
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00